COMMUNIQUÉS West-GlobeNewswire

NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment
19/05/2026
New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease. SANTA ANA, Calif., May 19, 2026 ( [...]
Vanqua Bio to Present Positive Biomarker Data from Ongoing Phase 1b Study at Upcoming Medical Conferences
19/05/2026
CHICAGO, May 19, 2026 (GLOBE NEWSWIRE) -- Vanqua Bio , a clinical-stage biopharmaceutical company, announced that the company will present interim data from its Phase 1b study at World Parkinson’s Congress and the GBA1 [...]
Prana IV Therapy Highlights Emerging Research on Magnesium’s Role in Stress and Neurological Function
19/05/2026
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- The global magnesium supplement market continues to grow (estimated at a 7–8% CAGR) as more consumers become concerned about magnesium deficiency, stress-related [...]
Matisse Pharmaceuticals receives FDA IND clearance for isupartob sodium
19/05/2026
Geleen, May 19 th , 2026 Matisse Pharmaceuticals B.V., a clinical stage company developing a medicinal product for the treatment of sepsis, today announced that the U.S. Food and Drug Administration (FDA) has cleared [...]
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
19/05/2026
Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC Last year’s awardees recently [...]
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities
19/05/2026
Increase in stockholder equity and note extension strengthen Company’s ability to advance pancreatic cancer development strategy OCALA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“ [...]
XORTX Announces Closing of US$5 Million Public Offering
19/05/2026
CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing [...]
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
19/05/2026
Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+ 1 TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or [...]
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
19/05/2026
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that [...]
Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
19/05/2026
Milestone advances commercial and manufacturing readiness ahead of anticipated pivotal study scale-up BURLINGTON, Mass, May 19, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") ( [...]
Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease
19/05/2026
SHANGHAI, May 19, 2026 (GLOBE NEWSWIRE) -- Risen Pharma, a clinical-stage biotech company focusing on the development and commercialization of high-need, patient-accessible therapeutics, today announced the initiation [...]
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
19/05/2026
Partnership to deliver a novel AI-native integrated CNS oncology platform Platform will unify and analyze Plus’ proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision neuro-oncology [...]
HEPHAISTOS-Pharma appoints Stephan Braun as Chief Medical Officer to lead clinical development strategy
19/05/2026
HEPHAISTOS-Pharma appoints Stephan Braun as Chief Medical Officer to lead clinical development strategy Former ImCheck Therapeutics clinical leader joins HEPHAISTOS-Pharma as the company prepares to advance its lead [...]
AdrenoMed Highlights Need for Personalized Therapies in Septic Shock Amid New Sepsis Guidelines and U.S. Policy Initiative
19/05/2026
Hennigsdorf / Berlin (Germany), May 19, 2026 (GLOBE NEWSWIRE) -- Press Release AdrenoMed Highlights Need for Personalized Therapies in Septic Shock Amid New Sepsis Guidelines and U.S. Policy Initiative 2026 Surviving [...]
GenoSafe advances CLIA pathway for transatlantic ATMP development
19/05/2026
GenoSafe advances CLIA pathway for transatlantic ATMP development CLIA registration enables GenoSafe to support testing of samples from U.S.-based patients enrolled in clinical trials. This milestone strengthens [...]
FEATOL Introduces Ergonomic Wrist Support for Modern Repetitive Strain Challenges
19/05/2026
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- FEATOL has introduced the FEATOL 2 Pack Carpal Tunnel Wrist Brace, a wrist support solution for daily stabilization, pain relief, and recovery support. The brace is made for [...]
Transactions in connection with share buy-back program
19/05/2026
Company announcement no. 17 - 26 19 May 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
19/05/2026
BASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, [...]
Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial
19/05/2026
-- STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors. -- Study to evaluate tertiary [...]

Pages